| P50 | author | Bernard J Gersh | Q100694590 |
| P2093 | author name string | Gerd Heusch | |
| P2860 | cites work | Outcomes From Selective Use of Thrombectomy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: An Analysis of the British Cardiovascular Intervention Society/National Institute for Cardi | Q40079189 |
| | Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset | Q40079196 |
| | Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials | Q40811915 |
| | Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention | Q40815387 |
| | Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction: The BEtA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial | Q40928907 |
| | Effect of Ischemia Duration and Door-to-Balloon Time on Myocardial Perfusion in ST-Segment Elevation Myocardial Infarction: An Analysis From HORIZONS-AMI Trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). | Q40996247 |
| | Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury | Q41283732 |
| | Lethal Myocardial "Reperfusion Injury": The Opinions of Good Men. | Q41714795 |
| | Delayed treatment with hypothermia protects against the no-reflow phenomenon despite failure to reduce infarct size | Q41778933 |
| | Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial | Q42614551 |
| | A single dose of erythropoietin in ST-elevation myocardial infarction | Q42923034 |
| | Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction | Q42940294 |
| | Postconditioning the human heart in percutaneous coronary intervention | Q42966179 |
| | TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. | Q43136849 |
| | Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action | Q43175053 |
| | Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial | Q43209386 |
| | A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction | Q43289264 |
| | Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. | Q43298149 |
| | Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. | Q43639262 |
| | Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial | Q43777913 |
| | The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial | Q43796510 |
| | Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion | Q43852730 |
| | Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris | Q43858379 |
| | The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction | Q43935007 |
| | Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). | Q43994700 |
| | Coronary microembolization during early reperfusion: infarct extension, but protection by ischaemic postconditioning | Q43999555 |
| | 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction | Q44144634 |
| | The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study | Q44182263 |
| | Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina | Q44209425 |
| | Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction | Q44244526 |
| | The Global Burden of Ischemic Heart Disease in 1990 and 2010: The Global Burden of Disease 2010 Study | Q22241915 |
| | ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies | Q24289195 |
| | Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning | Q24303818 |
| | Reducing myocardial infarct size: challenges and future opportunities | Q26775395 |
| | Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning | Q26995004 |
| | From ATP to PTP and Back: A Dual Function for the Mitochondrial ATP Synthase | Q27004110 |
| | Historical perspective on the pathology of myocardial ischemia/reperfusion injury | Q27010509 |
| | Myocardial conditioning: opportunities for clinical translation | Q27028002 |
| | Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning | Q28080777 |
| | Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning | Q28187266 |
| | Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials | Q28202129 |
| | The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection | Q28248925 |
| | Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study | Q28648455 |
| | Mitochondrial control of cell death | Q29617739 |
| | Effect of microvascular obstruction and intramyocardial hemorrhage by CMR on LV remodeling and outcomes after myocardial infarction: a systematic review and meta-analysis | Q30408532 |
| | Pre-infarction angina and outcomes in non-ST-segment elevation myocardial infarction: data from the RICO survey | Q30583477 |
| | Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial | Q33535020 |
| | No evidence for activated autophagy in left ventricular myocardium at early reperfusion with protection by remote ischemic preconditioning in patients undergoing coronary artery bypass grafting | Q33568009 |
| | Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI) | Q33606173 |
| | ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology | Q33886193 |
| | Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology | Q33972677 |
| | Myocardial edema: a translational view. | Q34143745 |
| | Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. | Q54325677 |
| | SnapShot: Necroptosis. | Q54337095 |
| | Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. | Q54431544 |
| | Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo. | Q54513464 |
| | Effect of postconditioning in patients with ST-elevation acute myocardial infarction. | Q54539684 |
| | Isolation of HTLV-I from cerebrospinal fluid of a patient with myelopathy. | Q55243770 |
| | Lack of Benefit of Ischemic Postconditioning After Routine Thrombus Aspiration During Reperfusion | Q57718773 |
| | A Prospective Randomized Trial of Thrombectomy Versus No Thrombectomy in Patients With ST-Segment Elevation Myocardial Infarction and Thrombus-Rich Lesions | Q57763892 |
| | Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore | Q57902814 |
| | A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction | Q38500796 |
| | Coronary microvascular obstruction in acute myocardial infarction | Q38585777 |
| | Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage | Q39433798 |
| | Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction | Q39557839 |
| | Leukocytes and ischemia-induced myocardial injury | Q39735537 |
| | Association between clinical presentations before myocardial infarction and coronary mortality: a prospective population-based study using linked electronic records | Q34175999 |
| | Effect of ischemic postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial | Q34297010 |
| | Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention | Q34370643 |
| | Remote ischemic conditioning. | Q34458416 |
| | The "no-reflow" phenomenon after temporary coronary occlusion in the dog. | Q34471387 |
| | Cyclosporine before PCI in Patients with Acute Myocardial Infarction | Q34491582 |
| | Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized LIPSIA CONDITIONING trial | Q34494832 |
| | Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. | Q34496755 |
| | A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery | Q34496763 |
| | ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! | Q34499610 |
| | Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial | Q34511207 |
| | The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system | Q34578586 |
| | Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. | Q34641812 |
| | Myocardial reperfusion injury. | Q34687124 |
| | Cellular mechanisms of ischemia-reperfusion injury | Q35073954 |
| | Cardiovascular remodelling in coronary artery disease and heart failure | Q35090566 |
| | Randomized phase 2 trial of intracoronary nitrite during acute myocardial infarction | Q35121830 |
| | Role of the mitochondrial permeability transition in myocardial disease | Q35204734 |
| | Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection? | Q35286339 |
| | Impact of cardiovascular risk factors and medication use on the efficacy of remote ischaemic conditioning: post hoc subgroup analysis of a randomised controlled trial | Q35332300 |
| | Myocardial 'stunning' in man | Q35544831 |
| | Cardiomyocyte death: mechanisms and translational implications | Q35657122 |
| | Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis | Q35897908 |
| | Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion | Q35897942 |
| | Remote ischemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI): study protocol for a randomized controlled trial | Q36040821 |
| | Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? | Q36053187 |
| | The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. | Q36122804 |
| | Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection | Q36141133 |
| | The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology. | Q36146320 |
| | Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials | Q36345758 |
| | Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial | Q36364317 |
| | Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion | Q36479325 |
| | Preinfarction angina reduces infarct size in ST-elevation myocardial infarction treated with percutaneous coronary intervention | Q36714753 |
| | Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts | Q36763104 |
| | Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial | Q44553655 |
| | Door-to-balloon time and mortality among patients undergoing primary PCI. | Q44655278 |
| | Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial | Q44785279 |
| | EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention | Q45022516 |
| | Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia | Q45226110 |
| | Postconditioning reduces enzymatic infarct size and improves microvascular reperfusion in patients with ST-segment elevation myocardial infarction | Q45340809 |
| | Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration. | Q46017623 |
| | Postconditioning attenuates no-reflow in STEMI patients | Q46051532 |
| | No cardioprotective benefit of ischemic postconditioning in patients with ST-segment elevation myocardial infarction | Q46152627 |
| | Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial | Q46205789 |
| | Effect of cyclosporine on reperfusion injury in acute myocardial infarction | Q46453592 |
| | Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial | Q46504683 |
| | A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). | Q46528602 |
| | Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning | Q46546394 |
| | Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice | Q46650190 |
| | Postconditioning the human heart | Q46722557 |
| | Differences in the profile of protection afforded by TRO40303 and mild hypothermia in models of cardiac ischemia/reperfusion injury. | Q46740130 |
| | Long-term benefit of postconditioning | Q46758924 |
| | Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials | Q46928598 |
| | Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts | Q46974556 |
| | Effect of thrombus aspiration on infarct size and left ventricular function in high-risk patients with acute myocardial infarction treated by percutaneous coronary intervention. Results of a prospective controlled pilot study | Q47193963 |
| | Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention | Q47199092 |
| | Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction | Q47305177 |
| | The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs | Q47325541 |
| | Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? | Q47355940 |
| | Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention | Q47360567 |
| | Prodromal angina limits infarct size. A role for ischemic preconditioning | Q47361194 |
| | Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis. | Q47378684 |
| | Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs | Q47382878 |
| | Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. | Q47655455 |
| | Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study | Q47978393 |
| | Outcomes 1 year after thrombus aspiration for myocardial infarction | Q48518414 |
| | Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. | Q50647596 |
| | Remote Ischemic Conditioning in Patients With Myocardial Infarction Treated With Primary Angioplasty: Impact on Left Ventricular Function Assessed by Comprehensive Echocardiography and Gated Single-Photon Emission CT. | Q50695540 |
| | Autophagy gene fingerprint in human ischemia and reperfusion. | Q50897122 |
| | No post-conditioning in the human heart with thrombolysis in myocardial infarction flow 2-3 on admission. | Q51106338 |
| | The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction. | Q51124858 |
| | Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial. | Q51172887 |
| | Deferred versus conventional stent implantation in patients with ST-segment elevation myocardial infarction (DANAMI 3-DEFER): an open-label, randomised controlled trial. | Q51387330 |
| | Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. | Q51434527 |
| | Remote conditioning: the future of cardioprotection? | Q51498606 |
| | Comparison of rheolytic thrombectomy before direct infarct artery stenting versus direct stenting alone in patients undergoing percutaneous coronary intervention for acute myocardial infarction. | Q51689826 |
| | Combined adenosine and lidocaine administration limits myocardial reperfusion injury. | Q51729201 |
| | Multiple protective pathways against reperfusion injury: a SAFE path without Aktion? | Q51752588 |
| | Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. | Q51758898 |
| | Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. | Q51808889 |
| | Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study. Comparison of unconscious and conscious dog models. | Q51827797 |
| | Aspiration coronary thrombectomy for acute myocardial infarction increases myocardial salvage: single center randomized study. | Q53250008 |
| | Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. | Q54066541 |
| | Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular "stunning". | Q54092323 |
| | New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop | Q37007953 |
| | Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. | Q37111331 |
| | The mitochondrial permeability transition pore and ischemia-reperfusion injury | Q37163574 |
| | Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts | Q37277256 |
| | Cardioprotective signaling to mitochondria | Q37360936 |
| | Myocardial no-reflow in humans | Q37553284 |
| | Coronary microembolization: from bedside to bench and back to bedside | Q37626321 |
| | Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology | Q37744271 |
| | The coronary circulation in cardioprotection: more than just one confounder. | Q37946255 |
| | Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection. | Q37998218 |
| | Contribution of calpains to myocardial ischaemia/reperfusion injury. | Q38025612 |
| | Cardioprotection: chances and challenges of its translation to the clinic | Q38055280 |
| | Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. | Q38075417 |
| | Cell death in the myocardium: my heart won't go on. | Q38119187 |
| | Current state of clinical translation of cardioprotective agents for acute myocardial infarction | Q38125980 |
| | Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered | Q38168199 |
| | The history of coronary reperfusion | Q38229561 |
| | Intramyocardial haemorrhage after acute myocardial infarction | Q38268870 |
| | What is Wrong With Cardiac Conditioning? We May be Shooting at Moving Targets | Q38334709 |
| | Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. | Q38376053 |
| | Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction | Q38376826 |
| | Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial | Q38394069 |
| | Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial | Q38400764 |
| | Evolving therapies for myocardial ischemia/reperfusion injury. | Q38413330 |
| | Prospective, multicenter, randomized, controlled pilot trial of peritoneal hypothermia in patients with ST-segment- elevation myocardial infarction | Q38415960 |
| | Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction | Q38433893 |
| | Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNI | Q38445186 |
| | Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia | Q38473330 |
| | Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial | Q38473353 |
| | Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial | Q38474127 |
| | STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication | Q38480556 |
| | Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial | Q38485558 |
| | Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction | Q38498683 |
| | Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial | Q38500791 |
| P433 | issue | 11 | |
| P921 | main subject | myocardial infarction | Q12152 |
| | pathophysiology | Q1135939 |
| | acute myocardial infarction | Q18558122 |
| P304 | page(s) | 774-784 | |
| P577 | publication date | 2016-06-26 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge | |
| P478 | volume | 38 | |